AVEO Oncology (AVEO) announced that it has commenced a Phase 1/2 clinical trial evaluating the combination of lead product candidate tivozanib and Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) in patients with advanced renal cell carcinoma. The Phase 1 portion of the study will evaluate escalating doses of tivozanib in combination with nivolumab while the Phase 2 will assess the optimal dose of tivozanib combined with nivolumab.